H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue [Yahoo! Finance]
Jade Biosciences, Inc. (JBIO)
Company Research
Source: Yahoo! Finance
Wainwright initiated coverage of Jade Biosciences with a Buy rating and $25 price target. The firm identified the company as being strategically positioned to secure a leadership role within the autoimmune market. The firm projects that JADE101, specifically for the treatment of immunoglobulin A nephropathy, could generate $926 million in risk-adjusted revenue by 2037. In Q3 2025, Jade Biosciences Inc. (NASDAQ:JBIO) highlighted major progress for its lead candidate, JADE101, and the introduction of a new development program, JADE201. Backed by a successful $135 million private placement completed in October, Jade extended its cash runway into H1 2028, positioning itself to hit several upcoming clinical milestones. Jade Biosciences is currently advancing JADE101, a selective anti-APRIL monoclonal antibody designed for patients with IgA nephropathy. The company presented preclinical data showing that JADE101 was well-tolerated in non-human primates, establishing a no-observed-advers
Show less
Read more
Impact Snapshot
Event Time:
JBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JBIO alerts
High impacting Jade Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
JBIO
News
- Jade Biosciences (NASDAQ:JBIO) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
- Jade Biosciences (NASDAQ:JBIO) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.MarketBeat
- Institutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last week [Yahoo! Finance]Yahoo! Finance
- Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
JBIO
Earnings
- 11/13/25 - Beat
JBIO
Sec Filings
- 1/30/26 - Form SCHEDULE
- 1/5/26 - Form 8-K
- 12/31/25 - Form EFFECT
- JBIO's page on the SEC website